Follow-up imaging after left atrial appendage closure.


Journal

Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317

Informations de publication

Date de publication:
11 2020
Historique:
received: 11 03 2020
revised: 17 06 2020
accepted: 21 06 2020
pubmed: 1 7 2020
medline: 15 9 2021
entrez: 1 7 2020
Statut: ppublish

Résumé

Because device-related thrombus (DRT) portends a poor prognosis after left atrial appendage closure with the Watchman device, surveillance transesophageal echocardiography (TEE) is recommended at 45 days and 1 year. However, oral anticoagulants are just discontinued at 45 days, rendering this early TEE unlikely to detect DRT. Indeed, DRT is most likely to occur after instituting aspirin monotherapy. The purpose of this study was to evaluate the alternative strategy of first TEE imaging (or computed tomography) at 4 months post-Watchman implantation. After Food and Drug Administration approval, consecutive patients undergoing Watchman implantation at 2 centers received TEE or CT at 4 months and 1 year, along with a truncated drug regimen: 6 weeks of an oral anticoagulant (or clopidogrel in a subset) plus aspirin, then 6 weeks of dual antiplatelet therapy, and finally aspirin monotherapy. Of the 530-patient cohort (mean age 78.7±7.9 years; 65.5% (n = 347) male; CHA Delaying the first imaging post-Watchman implantation to 4 months was associated with no IS between 45 days and 4 months, the "vulnerable" period of this follow-up strategy.

Sections du résumé

BACKGROUND
Because device-related thrombus (DRT) portends a poor prognosis after left atrial appendage closure with the Watchman device, surveillance transesophageal echocardiography (TEE) is recommended at 45 days and 1 year. However, oral anticoagulants are just discontinued at 45 days, rendering this early TEE unlikely to detect DRT. Indeed, DRT is most likely to occur after instituting aspirin monotherapy.
OBJECTIVE
The purpose of this study was to evaluate the alternative strategy of first TEE imaging (or computed tomography) at 4 months post-Watchman implantation.
METHODS
After Food and Drug Administration approval, consecutive patients undergoing Watchman implantation at 2 centers received TEE or CT at 4 months and 1 year, along with a truncated drug regimen: 6 weeks of an oral anticoagulant (or clopidogrel in a subset) plus aspirin, then 6 weeks of dual antiplatelet therapy, and finally aspirin monotherapy.
RESULTS
Of the 530-patient cohort (mean age 78.7±7.9 years; 65.5% (n = 347) male; CHA
CONCLUSION
Delaying the first imaging post-Watchman implantation to 4 months was associated with no IS between 45 days and 4 months, the "vulnerable" period of this follow-up strategy.

Identifiants

pubmed: 32603780
pii: S1547-5271(20)30623-8
doi: 10.1016/j.hrthm.2020.06.024
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1848-1855

Informations de copyright

Copyright © 2020 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Kenji Kuroki (K)

Cardiology Division, Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.

Shephal K Doshi (SK)

Cardiology Division, Pacific Heart Institute, Santa Monica, California.

William Whang (W)

Cardiology Division, Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.

Sarina Vanderzee (S)

Cardiology Division, Pacific Heart Institute, Santa Monica, California.

Crystal B Ducharme (CB)

Cardiology Division, Pacific Heart Institute, Santa Monica, California.

Yoshinari Enomoto (Y)

Cardiology Division, Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.

Sam Hanon (S)

Cardiology Division, Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.

Jacob S Koruth (JS)

Cardiology Division, Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.

Marc A Miller (MA)

Cardiology Division, Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.

Subbarao Choudry (S)

Cardiology Division, Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.

Aamir Sofi (A)

Cardiology Division, Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.

Noelle Langan (N)

Cardiology Division, Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.

Betsy Ellsworth (B)

Cardiology Division, Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.

Srinivas R Dukkipati (SR)

Cardiology Division, Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.

Vivek Y Reddy (VY)

Cardiology Division, Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: vivek.reddy@mountsinai.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH